Showing results (211-220 of 256) with videos related to

Sort By:
Pageof 26
Journal of the American College of Cardiology|April 23, 2021
Group Medical Visit and Microfinance Intervention for Patients With Diabetes or Hypertension in KenyaRajesh Vedanthan, Jemima H Kamano, Stavroula A Chrysanthopoulou, et al.
JACC. Advances|July 10, 2026
Inflammatory, Cardiac, and Lipid-Related Biomarkers in Relation to Residual MACE Risk in the REPRIEVE TrialSteven K Grinspoon, Christopher DeFilippi, Triin Umbleja, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 12, 2022
Asymptomatic SARS-CoV-2 Infection Is Common Among ART-Treated People With HIVEdgar T Overton, Isabelle R Weir, Markella V Zanni, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 26, 2025
Risk Assessment in a Global CVD Prevention Cohort of People with HIV by PCE, PREVENT, and SCORE2Steven K Grinspoon, Sophia Zhao, Esteban Martinez, et al.
JACC. Advances|May 15, 2025
Coronary Plaque, Inflammation, Subclinical Myocardial Injury, and Major Adverse Cardiovascular Events in the REPRIEVE SubstudyMichael T Lu, Heather J Ribaudo, Sara McCallum, et al.
The Journal of Clinical Investigation|September 9, 2025
Statin-dependent and -independent pathways are associated with major adverse cardiovascular events in people with HIVMárton Kolossváry, Irini Sereti, Markella V Zanni, et al.
JACC. Advances|September 10, 2024
Association of Cardiac Troponin T With Coronary Atherosclerosis in Asymptomatic Primary Prevention People With HIVChristopher deFilippi, Sara McCallum, Markella V Zanni, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 16, 2021
Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE TrialPamela S Douglas, Triin Umbleja, Gerald S Bloomfield, et al.
Blood Advances|January 10, 2024
Risk factors for clonal hematopoiesis of indeterminate potential in people with HIV: a report from the REPRIEVE trialRomit Bhattacharya, Md Mesbah Uddin, Aniruddh P Patel, et al.
Open Forum Infectious Diseases|April 10, 2025
Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial CohortEmma Davies Smith, Carlos Malvestutto, Heather J Ribaudo, et al.
Pageof 26